Siamab Therapeutics’ Antibody Drug Conjugates Show Promising Results in Ovarian Cancer

Siamab Therapeutics’ Antibody Drug Conjugates Show Promising Results in Ovarian Cancer
On Sept. 12, at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium in Seattle, Siamab Therapeutics declared that its new ST1 antibody drug conjugates (ADCs) have the ability to target chemotherapy-resistant ovarian cancer cells, showing strong efficacy in ovarian cancer models. “We have developed multiple anti-glycan antibodies and ADCs with unprecedented cancer specificity and efficacy in animal models. These findings hold promise for developing new cancer therapeutics for ovarian cancer patients with disease recurrence who have limited treatment options,” Jeff Behrens, president and CEO of Siamab Therapeutics, said in a press release. Siamab's focus is on optimizing rapid discovery and development of therapeutic antibodies that bind with unsurpassed accuracy and rate to a specific type of carbohydrate-based antigens (molecules that induce immune responses) on the surface of cancer cells called tumor-associated carbohydrate antigens (TACAs). TACAs' importance for cancer research lies on four separate issues: they are cancer specific, associated with chemoresistance, associated with metastasis, and able to act in a locally immunosuppressive way around solid tumors. ST1-ADCs, Siamab's flagship project, is designed to act as a missile targeting Sialyl-Tn (STn), a tumor-specific antigen expressed by multiple solid tumors like pancreatic, prostate and colon cancers, in addition to ovarian cancer. Also, STn defines a population of cells th
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *